Site provided by Valneva USA, Inc.

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

 

 

Make sure they’re protected
against Japanese encephalitis (JE).

JE Treatment

There is no specific treatment for JE; prevention is the best protection.3

 The only available care for JE survivors is supportive, which can range from immediate life support measures, to long-term rehabilitation.1,3,4

JE virus is the most important cause of viral encephalitis in Asia.1

– World Health Organization (WHO)

Reducing Risk of JE for Travelers to Asia


Since JE virus is transmitted through mosquito bites, strategies for reducing JE risk involve minimizing mosquito exposure. These include barrier protection, environmental protection, and vaccination.14

Barrier protection

includes using insect repellent on both skin and clothing, and wearing proper clothing whenever outdoors.14

Environmental protection

includes staying in accommodations with air-conditioned or well-screened rooms, or using bed nets and aerosol room insecticides.14

Reduced exposure

includes minimizing outdoor activities during peak biting hours, typically from dusk to dawn.14

CDC Guidelines for Vaccination15

VACCINATION IS RECOMMENDED for persons moving to a JE-endemic country to live, longer-term travelers (eg, 1 month or longer), and frequent travelers to JE-endemic areas.

CONSIDER RISK AND VACCINATE BASED ON:

  • Shorter-term travel itineraries (eg, less than 1 month) that increase risk of exposure to JE virus based on planned travel:
    • season
    • activities
    • location
    • accommodations
    • duration
  • Travel itineraries that have uncertain specific durations of travel, destinations, or activities

VACCINATION IS NOT RECOMMENDED for travelers with very low-risk itineraries, such as shorter-term travel limited to urban areas or travel that occurs outside of a well-defined JE virus transmission season.

Reducing Risk of JE for Travelers to Asia


Since JE virus is transmitted through mosquito bites, strategies for reducing JE risk involve minimizing mosquito exposure. These include barrier protection, environmental protection, and vaccination.14

Barrier protection

includes using insect repellent on both skin and clothing, and wearing proper clothing whenever outdoors.14

Environmental protection

includes staying in accommodations with air-conditioned or well-screened rooms, or using bed nets and aerosol room insecticides.14

Reduced exposure

includes minimizing outdoor activities during peak biting hours, typically from dusk to dawn.14

CDC Guidelines for Vaccination15

VACCINATION IS RECOMMENDED for persons moving to a JE-endemic country to live, longer-term travelers (eg, 1 month or longer), and frequent travelers toJE-endemic areas.

CONSIDER RISK AND VACCINATE BASED ON:

  • Shorter-term travel itineraries (eg, less than 1 month) that increase risk of exposure to JE virus based on planned travel:

    • season
    • activities
    • location
    • accommodations
    • duration
  • Travel itineraries that have uncertain specific durations of travel, destinations, or activities

VACCINATION IS NOT RECOMMENDED for travelers with very low-risk itineraries, such as shorter-term travel limited to urban areas or travel that occurs outside of a well-defined JE virus transmission season.

JE Checklist for Travel to Asia

Assess Risk of JE Virus Exposure

Destination, duration, activities

Barrier Protection & Mosquito Avoidance14

  • Insect repellent
  • Bed nets
  • Aerosol room insecticides
  • Minimal outdoor activity, including from dusk to dawn
  • Proper clothing whenever outdoors

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO.  Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

Valneva USA, Inc.
910 Clopper Road, Suite 160S
Gaithersburg, MD 20878, USA

Customer Service
+1 866 223 7118

Medical Information
+1 844 349 4276
     (8443-IXIARO)

This website is intended for US-based healthcare professionals.

1807-US-IX-044-0819 | Copyright © 2019 Valneva USA, Inc. All Rights Reserved